Envista Acquires Osteogenics Biomedical Business
May 17, 2022
Envista Holdings Corporation entered into a definitive agreement to acquire Osteogenics Biomedical, Allotech LLC and OBI Biologics (collectively “Osteogenics”), a developer of regenerative dental bone grafting products sold primarily under the Cytoplast brand. The deal, subject to customary regulatory approvals and expected to close in the third quarter, expands Envista’s capabilities in regenerative solutions for periodontists, oral and maxillofacial surgeons and implant dentistry; the transaction is not subject to a financing condition or shareholder vote.
- Buyers
- Envista Holdings Corporation
- Targets
- Osteogenics Biomedical Inc, Allotech LLC, OBI Biologics, Inc
- Industry
- Medical Devices
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Isto Biologics Acquires NovaBone Products LLC
August 4, 2026
Healthcare Services
Isto Biologics announced the acquisition of NovaBone Products LLC, a developer and manufacturer of synthetic bone graft products, from Halma plc. The deal, supported by Keensight Capital, adds NovaBone’s bioactive glass technologies to Isto’s bone graft substitutes platform and expands its geographic reach and surgical end-market presence.
-
Keensight Capital Acquires Majority Stake in Isto Biologics
September 22, 2025
Healthcare Services
Keensight Capital has agreed to acquire a majority stake in regenerative MedTech company Isto Biologics. Thompson Street Capital Partners (TSCP) will retain a minority stake alongside Isto’s management team.
-
Avista Healthcare Partners Acquires EBI Bone Healing Division from Highridge Medical
June 4, 2025
Medical Devices
Avista Healthcare Partners has acquired EBI, the bone healing division of Highridge Medical, marking Avista's 50th platform healthcare investment. The deal is a carve-out/divestiture from Highridge (a H.I.G. Capital portfolio company) intended to position EBI as a standalone leader in bone growth stimulation technologies.
-
OmniActive Health Technologies Acquires ENovate Biolife
November 4, 2024
Food & Beverage
OmniActive Health Technologies has acquired ENovate Biolife to expand its portfolio of clinically validated botanical and specialty active ingredients for dietary supplements, functional foods and sports nutrition. The acquisition strengthens OmniActive's R&D, clinical and commercial capabilities and aims to accelerate global distribution of ENovate's ingredients such as Muvz, RedNite and Oxyjun.
-
BioIVT Acquires ZenBio
August 21, 2024
Healthcare Services
BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.
-
Avanos Medical Acquires OrthogenRx for $160M
December 13, 2021
Medical Devices
Avanos Medical, Inc. has entered into a definitive agreement to acquire OrthogenRx, Inc. for $160 million ($130M cash at closing plus up to $30M contingent on milestones). The acquisition adds OrthogenRx's FDA-approved viscosupplementation products GenVisc 850 and TriVisc to Avanos' chronic pain portfolio to expand its continuum-of-care offerings for knee osteoarthritis patients.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.